Zhejiang Cancer Hospital
🇨🇳China
A Multi-omics-based Metabolic Typing Study of Gastric Cancer
Active, not recruiting
- Conditions
- Gastric CancerMulti-omicsDiagnosis
- Interventions
- Other: Without any intervention
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 480
- Registration Number
- NCT06134011
- Locations
- 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China
Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.
Phase 2
Recruiting
- Conditions
- Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
- Interventions
- Drug: dalpiciclib; fluvestrant; compound gossypol acetate tablets
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT06133088
- Locations
- 🇨🇳
zhejiangCH, Hangzhou, Zhejiang, China
The Effects of Hemodilution Methods in Patients Undergoing Primary Debulking Gynaecological Surgery
Not Applicable
Completed
- Conditions
- Ovarian Neoplasm Epithelial
- Interventions
- Other: acute normovolemic hemodilution (ANH)Other: acute hypervolemic hemodilution (AHH)
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 144
- Registration Number
- NCT06103214
Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT06092645
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
Phase 2
Recruiting
- Conditions
- Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma Refractory
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT06086197
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Development of Novel Gastric Cancer Screening and Diagnosis Technologies Using Tongue Imaging and Study of Tongue Image Changes Mechanisms
Recruiting
- Conditions
- Tongue ImagesGastric CancerDiagnosis
- Interventions
- Diagnostic Test: Tongue imaging, tougue coating, saliva, and feces
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100000
- Registration Number
- NCT06078930
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06055816
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
Phase 2
Recruiting
- Conditions
- Gastric CancerPeritoneal MetastasesAscites, Malignant
- Interventions
- Other: Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT06046963
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy
Recruiting
- Conditions
- CholangiocarcinomaBiliary Tract Tumor
- Interventions
- Other: Blood samples, tumor biopsy specimens will be collected
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT06048289
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Phase 3
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer Stage III
- Interventions
- Radiation: radiotherapyDrug: Platinum-Based DrugDrug: Immunotherapeutic AgentDrug: Immunotherapy
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 105
- Registration Number
- NCT06031597
© Copyright 2025. All Rights Reserved by MedPath